eli lilly - Search News

Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for diabetes and obesity.

AOL · 9d

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Recently,

MarketWatch · 1d

Eli Lilly & Co. stock outperforms competitors on strong trading day

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top

Barron's on MSN · 18h

Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock.

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company.

Hosted on MSN · 1d

Do Options Traders Know Something About Lilly (LLY) Stock We Don't?

Investors in Eli Lilly and Company LLY need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $400.00 Call had some of the highest implied volatility of all equity options today.

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Ibj.com3d

Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

7don MSN

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

FiercePharma5d

Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

11d

Eli Lilly: Market Overreacted

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Yahoo Finance2d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the ...

The Motley Fool13d

Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics